European Commission grants authorization in adults and children 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment -- BOSTON, May 01, 2026 (GLOBE ...
Eli Lilly and Company (NYSE:LLY) executives said the drugmaker started 2026 with “a strong start,” pointing to sharp first-quarter revenue growth, continued demand for its incretin medicines, a newly ...
Company positions itself as the central research hub for patients, clinicians, and compounding pharmacies tracking the ...
Press release - No. 9 / 2026 The Zealand Pharma Board of Directors proposes to elect Camilla Sylvest to the Board of ...
BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (Nasdaq: BRTX), a late-stage clinical ...
In an industry where the typical sample is a size zero, weight has always been central to a model’s success. But now, GLP-1 ...
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for ...
On March 19, Truist began coverage of Altimmune Inc. (NASDAQ:ALT) with a $12 price target, leading to a whopping 315% upside ...
He was the founder of Regal Traders (later Regal Group), one of the UAE’s earliest textile businesses, established in 1952 ...
Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, ...
Eli Lilly's newly launched oral weight-loss drug, Foundayo, was prescribed 5,612 times in the U.S. in the third week after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results